RBC Capital raised the firm’s price target on GoodRx to $7 from $5 and keeps a Sector Perform rating on the shares. The company’s positive pre-announcement for Q4 and a raise in FY24 growth outlook was driven by an uptick in seasonal respiratory illness as well as volume increases tied to direct retailer contracting, both of which should carry into Q1, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GDRX:
- GoodRx price target raised to $7.50 from $5.50 at Truist
- GoodRx Stock (NASDAQ:GDRX) Gained on Upbeat Q4 Preliminary Results
- GoodRx pre-announcement ‘directionally positive,’ says Wells Fargo
- GoodRx sees FY23 revenue $749M-$751M, consensus $744.26M
- GoodRx reports preliminary Q4 revenue $195M-$197M, consensus $190.77M